Navigation Links
Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference

- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions -

SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999 will be presented at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO), which is being held June 1 to 5 in Chicago, Illinois.

    -- Data from the Phase I trials of XL880 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics oral

       abstract presentation session at 9:00 a.m. CT on Saturday, June 2, in

       room E354b. (Abstract #3526)


    -- Data from the Phase II trials of XL999 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics poster

       session at 8:00 a.m. on Sunday, June 3, in S Hall A2. (Abstract #3591)

Additionally, four abstracts from Phase I studies of XL184 (Abstract #14031), XL647 (Abstract #14044) and Phase II studies of XL880 (Abstract #15601) and XL999 (Abstract #18112) will be published in abstract form but will not be presented at the meeting.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth
'"/>




Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
2. OXiGENE Abstracts Published in ASCO Program
3. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
5. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
9. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Thomson Reuters Partners With Sagient Research 13050 1Thomson Reuters Partners With Sagient Research 13050 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 1NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 3Number of Underweight Kids in U S Continues to Shrink 51798 1
...KERB Demonstrates Activity in Combination with Oth...ss A Range of Breast Cancer Settings, - First Pha...R2 and VEGF, pathways with two oral, small molecul...ib) demonstrates activity in first-line HER2 (ErbB...er(1) - Phase II results combining TYKERB and AVA...
...ICAGO, May 31 Millennium Pharmaceuticals, The Tak...tion of results from three,clinical trials of VELC...complete remission(1) (CR) rates in patients with ...f the best predictors of long-term survival. These... at the American Society,of Clinical Oncology (ASC...
Other Medicine Technology:New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 2New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 3New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 4New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 6New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 7New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 8New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 9New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 10Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
...t Washington University School of Medicine in St. ...pic worms to survive in a low-oxygen, or hypoxic, ...e implications for conditions such as stroke, hear...the Jan. 30 issue of the journal Science . , "In...
... Today, Jiffy Lube® service centers in S...entral Coast of California, the Spokane and Tri-Ci...nounce their participation in the second year of t... the nation,s number one killer of women and men, ...
... illness in cattle months before symptoms appear, ...thDay News) -- A simple, inexpensive DNA blood tes...cattle months before they show any clinical signs ...brain samples from dead animals. The ability to te...
... (BRONX, NY) Men who develop prostate cancer face...f they carry a so-called breast cancer gene mutati... Medicine of Yeshiva University report in today,s ... The study, involving 979 men with prostate cancer...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) c...D filing with the Securities and Exchange Commissi...filiated funds announcing their intent to nominate... this action. , , Amylin,s Corporate Governance C...
...nly used to improve physical function, decrease sy...ow back or neck pain. Numerous randomized trials a...s practice, and studies suggest that individually ...on, including who is prescribing it, who is gettin...
Other Medicine News:Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 2Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 2Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 4Health News:Blood Test for 'Mad Cow' Disease May Be Near 2Health News:Gene mutations increase risk for aggressive prostate cancer 2Health News:Gene mutations increase risk for aggressive prostate cancer 3Health News:Exercise underutilized for chronic back and neck pain 2Health News:Exercise underutilized for chronic back and neck pain 3
Bechert Nucleus Rotator
Lambert Membrane Hook-Pick - Right
Olk Angled Retinal Pick - 150 Degree
Sweeney Manipulator Cracker
Medicine Products: